Monitoring glucose levels after heart attacks in diabetic patients
Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes
This study tests if using continuous glucose monitors can help people with type 2 diabetes who have had a heart attack keep their blood sugar levels stable and reduce the risk of serious heart problems over six months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Imperial College London Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT05431296 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of continuous glucose monitoring (CGM) on glycemic control in individuals with type 2 diabetes who have experienced an acute myocardial infarction. Participants will be randomly assigned to either receive real-time CGM or blinded CGM, with the aim of maintaining blood glucose levels within a target range for six months post-discharge. The study will also explore the relationship between glycemic control and major cardiac events or mortality during this period. Data will be collected through regular reviews and adjustments to diabetes treatment based on CGM readings.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with type 2 diabetes who have recently experienced an acute myocardial infarction.
Not a fit: Patients with HbA1c levels below 48mmol/mol or those who have undergone bariatric surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve glycemic control and reduce the risk of adverse cardiac events in diabetic patients after a heart attack.
How similar studies have performed: Previous studies have shown promising results with continuous glucose monitoring in managing diabetes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: From the Hammersmith Hospital In-patient Cardiology Services: * Adults aged \>18 years * Known or newly diagnosed type 2 diabetes * Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and/or insulin * Admitted to Hammersmith Hospital cardiology inpatient services with ACS * Raised blood troponin level on admission From Imperial College Healthcare Trust Diabetes and Cardiology Clinics: * Adults aged \>18 years * Known type 2 diabetes * Previous acute coronary syndrome within the last 10 years but \> 6 months ago * Taking one or more oral hypoglycaemic agent and /or GLP1 receptor analogue, and/or insulin Exclusion Criteria: From the Hammersmith Hospital In-patient Cardiology Services: * HbA1c \<48mmol/mol * People who have previously had bariatric surgery * People taking hydroxyurea * People who undergo haemodialysis or peritoneal dialysis * Unable to participate due to other factors, as assessed by the Chief Investigators * Pregnancy as determined by clinical team * Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year From Imperial College Healthcare Trust Diabetes and Cardiology Clinics: * HbA1c \<48mmol/mol * People who have previously had bariatric surgery * People taking hydroxyurea * People who undergo haemodialysis or peritoneal dialysis * Unable to participate due to other factors, as assessed by the Chief Investigators * Pregnancy as determined by clinical team * Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year * Previous acute coronary syndrome more than 10 years ago or within the last 6 months Withdrawal criteria * The subject has a serious event related to the study * Investigated initiated discontinuation of study due to participation or equipment concerns * Withdrawal of consent
Where this trial is running
London
- Hammersmith Hospital inpatient cardiology services — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Monika Reddy, MBChB, PhD — Imperial College London
- Study coordinator: Monika Reddy, MBChB, PhD
- Email: m.reddy@imperial.ac.uk
- Phone: 020 3311 1062
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.